Literature DB >> 14652433

Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.

A Devaprasath1, G Chacko.   

Abstract

BACKGROUND: About 10% of meningiomas behave aggressively and are graded atypical or malignant with important therapeutic and prognostic implications. Routine histological parameters are inconsistent in the assessment of their aggressive behavior. AIMS: The aim of this study was to find a threshold level of the MIB-1 labeling index (MIB-1 LI) with the highest diagnostic validity in predicting histological atypia in a meningioma. SETTING AND
DESIGN: This was a retrospective study of all atypical and malignant meningiomas diagnosed at our center between January 1995 and June 2000 and which were identified from the General Pathology Registry.
MATERIAL AND METHODS: These meningiomas were assessed histologically with respect to the individual criteria of atypia. They were categorized according to the WHO 2000 classification as benign, atypical and anaplastic meningiomas, WHO Grades I, II and III respectively and by immunohistochemical analysis using the MIB-1 monoclonal antibody. STATISTICAL ANALYSIS: The diagnostically useful cut-off level for the prediction of atypia was estimated by calculating the sensitivity and specificity of the MIB-1 LI at various levels and a receiver operated characteristic (ROC) analysis was performed. The correlation between the individual histological parameters was studied and the MIB-1 LI was obtained using Fisher's exact test.
RESULTS: Of the 40 meningiomas studied 21 were benign, 16 atypical and 3 anaplastic. Atypical tumors had a higher MIB-1 LI than benign tumors, with diagnostic validity highest at a threshold of 7%, with a sensitivity of 0.86 and a specificity of 0.93, giving a likelihood ratio of 17. The MIB-1 LI correlated well with mitotic activity and the other individual criteria in the WHO 2000 definition of atypia in a meningioma. MIB-1 LI did not, however, correlate well with brain invasion.
CONCLUSION: The MIB-1 LI has the highest validity in the diagnosis of atypia in meningiomas at a threshold level of 7%. The MIB-1 LI used in conjunction with histological features can help in making a recommendation regarding potentially aggressive behavior in meningiomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652433

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  5 in total

1.  The clinical significance of MIB-1 labeling index in pituitary adenomas.

Authors:  Geeta Chacko; Ari G Chacko; Kalman Kovacs; Bernd W Scheithauer; Sunithi Mani; J P Muliyil; M S Seshadri
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

2.  Histopathological and Immunohistochemical Evaluation of Meningiomas with Reference to Proliferative Markers p53 and Ki-67.

Authors:  Ramesh Babu Telugu; Amit Kumar Chowhan; Nandyala Rukmangadha; Rashmi Patnayak; Bobbidi Venkata Phaneendra; Bodapati Chandra Mowliswara Prasad; Mandyam Kumaraswamy Reddy
Journal:  J Clin Diagn Res       Date:  2016-01-01

3.  The Study of MIB-1 LI and CD 34 As A Marker of Proliferative Activity and Angiogenesis in Different Grades of Meningioma.

Authors:  Harishkumar Bohra; Khushi Ram Rathi; Sharmila Dudani; Ashish Bohra; Sumit Vishwakarma; Kavita Sahai
Journal:  J Clin Diagn Res       Date:  2016-08-01

4.  CD44 Expression in Meningioma and its Correlation with Proliferation Indices.

Authors:  Rasha Ramadan Mostafa; Rasha Ahmed Khairy
Journal:  J Clin Diagn Res       Date:  2017-08-01

5.  Atypical meningioma: a retrospective analysis of six cases and literature review.

Authors:  Yiming Liang; Bo Ning; Xing Hua; Zhiping Liang; Jingchao Ye; Fangyi Yu; Zhilei Xu; Jiaxiang Chen
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.